Virology and oncology treatments specialist Gilead Sciences (GILD -0.32%)reported third-quarter results on Wednesday, Nov. 6, that topped analysts' consensus estimates on top- and bottom lines. 024. Total revenue of $7.5 billion rose 7% from the prior year, largely due to robust sales of its HIV and oncology products. Adjusted earnings per share (EPS) of $2.02 easily exceeded estimates of $1.51 but fell short on a year-over-year basis primarily due to a $1.75 billion impairment charge.
The quarter saw substantial revenue growth, encouraging confidence in Gilead's product lines and operating efficiency, as noted in the report by CEO Daniel O'Day.
| Metric | Q3 2024 | Analysts Estimate | Q3 2023 | Change (YOY) |
|---|---|---|---|---|
| Revenue | $7.54 billion | $7.01 billion | $7.05 billion | 7% |
| Non-GAAP EPS | $2.02 | $1.51 | $2.29 | (12%) |
| HIV product sales | $5.1 billion | N/A | $4.7 billion | 9% |
| Oncology product sales | $816 million | N/A | $769 million | 6.1% |
Source: Gilead Sciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. GAAP = Generally accepted accounting principles.
Overview of Gilead Sciences
Gilead Sciences is a leading biopharmaceutical company focusing on antiviral drugs used in the treatment of HIV, hepatitis, and oncology. With a diverse portfolio, Gilead is a major player in its field, frequently seeking to expand through research and development and strategic acquisitions.
Recently, Gilead's efforts have revolved around bolstering its core virology and oncology segments while enhancing its R&D pipeline. The firm prioritizes expanding its intellectual property to protect its innovative therapies, maintaining a strong market position by addressing unmet medical needs and ensuring competitive pricing strategies.
Financial Performance Highlights
Gilead's upturn in revenue was mainly driven by its HIV and oncology product lines. Biktarvy, an HIV treatment, saw a 13% sales increase to $3.5 billion due to heightened demand and better pricing strategies. Oncology sales totaled $816 million, spurred by a 17% rise in Trodelvy sales to $332 million, reflecting growth in both demand and market reach.
Despite these advances, Gilead reported lower earnings as non-GAAP EPS dropped to $2.02 compared to last year's $2.29. This decline stemmed largely from a $1.75 billion impairment of assets from its Immunomedics subsidiary. A strategic expansion to develop its pipeline led Gilead to slightly reduce R&D spending to $1.4 billion due to the completion of certain clinical activities.
The company also enhanced its patent strength through a $3.9 billion acquisition of CymaBay Therapeutics in March 2024, underscoring its commitment to securing exclusive product rights amidst rising competitive pressures. Furthermore, Gilead achieved FDA approvals in primary biliary cholangitis and aimed to secure U.S. market entry for lenacapavir, impacting the company's regulatory and compliance strategies.
Looking Ahead
Gilead increased its full-year guidance, now projecting product sales to range from $27.8 billion to $28.1 billion, coupled with improved non-GAAP EPS guidance between $4.25 and $4.45, up from prior guidance of $3.60 to $3.90. This improved forecast emanates from strong demand anticipation across its primary product lines and diligent expense management.
As Gilead navigates the upcoming quarters, priorities include expanding AI-driven research capacities and potentially quickening drug discovery. Investors should monitor new product launches such as lenacapavir, expected to bolster Gilead's lead in HIV prevention. Continued advancements and R&D investments are vital for maintaining growth momentum amidst competitive market challenges.
